Consumption of trastuzumab in the Oncological Mixtures Unit of Edgardo Rebagliati Martins National Hospital, January-December 2009

Authors

  • Jim W. Gallegos Facultad de Farmacia y Bioquímica, Universidad Nacional Mayor de San Marcos, Lima, Perú.
  • José R. Juárez Facultad de Farmacia y Bioquímica, Universidad Nacional Mayor de San Marcos, Lima, Perú.
  • Ada Ascarza Hospital Nacional Edgardo Rebagliati Martins-EsSALUD.
  • Mildred R. Dorregaray Hospital Nacional Edgardo Rebagliati Martins-EsSALUD.

DOI:

https://doi.org/10.15381/ci.v14i2.3166

Keywords:

trastuzumab, Mixtures Oncologic Unit (UMO), medical oncology, chemotherapy regimen, monoclonal antibody.

Abstract

The consumption of trastuzumab in oncological mixtures Unit (UMO) of the Hospital Nacional Edgardo Rebagliati Martins was studied during 2009 through retrospective descriptive analysis of the worksheets from the UMO and using of Hospital Management System (SGH) and analysis of written and dispensed prescriptions. The results show that the cost accounting of chemotherapy schemes was S/.72798,21 for each patient, still the most widely consumed trastuzumab more ixabepilone mixture with an average cost for six cycles S/. 68684, 52. The UMO attended 542 prescriptions and 521 preparations with trastuzumab, which generated an expense of S/. 3798426 and refunds amounted to S/. 704442, this generated a savings of 18,55%.

Downloads

Published

2011-12-30

Issue

Section

Artículos Originales

How to Cite

1.
Gallegos JW, Juárez JR, Ascarza A, Dorregaray MR. Consumption of trastuzumab in the Oncological Mixtures Unit of Edgardo Rebagliati Martins National Hospital, January-December 2009. Ciencia e investigación [Internet]. 2011 Dec. 30 [cited 2024 Jul. 3];14(2):22-8. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/farma/article/view/3166